{"id":496175,"date":"2021-05-20T06:33:09","date_gmt":"2021-05-20T10:33:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-to-present-preclinical-data-highlighting-anti-tumor-activity-and-tolerability-of-xtx202-at-the-2021-asco-annual-meeting\/"},"modified":"2021-05-20T06:33:09","modified_gmt":"2021-05-20T10:33:09","slug":"xilio-therapeutics-to-present-preclinical-data-highlighting-anti-tumor-activity-and-tolerability-of-xtx202-at-the-2021-asco-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/xilio-therapeutics-to-present-preclinical-data-highlighting-anti-tumor-activity-and-tolerability-of-xtx202-at-the-2021-asco-annual-meeting\/","title":{"rendered":"Xilio Therapeutics to Present Preclinical Data Highlighting Anti-Tumor Activity and Tolerability of XTX202 at the 2021 ASCO Annual Meeting"},"content":{"rendered":"

<\/p>\n

Xilio Therapeutics to Present Preclinical Data Highlighting Anti-Tumor Activity and Tolerability of XTX202 at the 2021 ASCO Annual Meeting<\/b><\/p>\n

Data demonstrated that XTX202, an engineered, tumor-selective IL-2, increased tumor growth inhibition without dose-limiting toxicities in preclinical studies<\/i><\/p>\n

Company plans to submit IND application for XTX202 in second half of 2021<\/i><\/p>\n

WALTHAM, Mass.–(BUSINESS WIRE<\/a>)–
\nXilio Therapeutics, a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, announced today the presentation of data from preclinical studies of XTX202, its tumor-selective interleukin-2 (IL-2) product candidate, demonstrating selective anti-tumor activity and favorable tolerability with no systemic toxicity observed. The data will be reported in a poster entitled \u201cXTX202, a protein-engineered IL-2, exhibits tumor-selective activity in mice without peripheral toxicities in non-human primates<\/i>\u201d at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. The poster will be made available on the ASCO Annual Meeting website at the start of the meeting on June 4, 2021 at 9am ET.\n<\/p>\n

\nXilio is leveraging its proprietary platform to engineer novel molecules that are designed to be activated in the tumor microenvironment (TME) and have the potential to result in localized, tumor-selective clinical activity without dose-limiting toxicities. XTX202, Xilio\u2019s lead cytokine product candidate, is an engineered form of IL-2 that is masked with a protein domain to prevent binding activity until cleaved off by TME-associated proteases.\n<\/p>\n

\n\u201cThe power of IL-2 to activate the immune system as a cancer therapeutic is promising, but utility of IL-2 agents has historically been greatly reduced due to toxicities,\u201d said R\u00f3n\u00e1n O\u2019Hagan, Ph.D., chief scientific officer of Xilio. \u201cWe have engineered XTX202 to overcome those challenges, with key features designed to ensure it is released and activated locally within the TME, where it selectively binds to IL-2 receptors on immune cells. We are excited to present these data which, for the first time, demonstrate selective tumor-inhibition and favorable tolerability of XTX202 in preclinical models. With these data, we plan to complete IND-enabling studies and submit an IND application in the second half of 2021 to evaluate XTX202 in patients with solid tumors.\u201d\n<\/p>\n

\nData reported in the poster are from preclinical studies in both mouse and non-human primate (NHP) models, including comparisons between XTX202 and XTX200, a non-masked, parent version of XTX202, as well as aldesleukin, a synthetic form of IL-2 approved for certain cancer indications by the U.S. Food and Drug Administration. Key data include:\n<\/p>\n